Missoula, Montana – Providence St. Patrick Hospital has been selected as one of five global locations to participate in the APOLLO research trial, which will examine the efficacy of the 29 French IntrepidTM transcatheter mitral valve replacement system. This device is designed to relieve mitral regurgitation by ensuring proper blood flow direction in the heart. It offers a minimally invasive alternative for mitral valve replacement, aiming to decrease the risk of complications.
Read also: Wells Fargo and Federal Home Loan Bank grant boosts Habitat for Humanity’s East Helena initiative
Providence St. Patrick Hospital sent out the following as reported by NBC Montana:
Providence St. Patrick Hospital announces its participation as one of only five global sites in the groundbreaking APOLLO research trial, studying the safety and efficacy of an investigative device called the 29 French IntrepidTM transcatheter mitral valve replacement system.
The device is a heart valve designed to help alleviate mitral regurgitation so that blood can flow through the heart in the intended direction. This revolutionary system promises a less invasive approach to mitral valve replacement, significantly reducing complications and expediting patient recovery.
The selection of St. Patrick Hospital underscores the institution’s exceptional clinical performance and commitment to pioneering research in cardiovascular medicine. With a dedicated team of cardiovascular specialists and a renowned research department, St. Pat’s has consistently demonstrated its capacity for innovation and excellence in patient care.
As a regional referral center, St. Patrick Hospital serves as a beacon of hope for patients from rural communities, offering access to cutting-edge therapies and clinical trials. Every referred patient undergoes thorough evaluation for potential inclusion in the APOLLO Trial, ensuring that the benefits of this groundbreaking treatment reach those who need it most. Providence Heart Institute-Montana is the largest and most advanced heart program in Western Montana and Eastern Idaho. Nine strategically located facilities ensure convenient access to unparalleled heart services for urban and rural communities.
“We are honored to be entrusted with the introduction of this groundbreaking technology,” said Dr. Dan Spoon, Division Chief of the Cardiovascular Service Line of Providence Heart Institute at Providence St. Patrick Hospital. “The APOLLO trial represents a significant advancement in cardiac care, and we are committed to playing a leading role in shaping the future of cardiovascular medicine.”
With the successful implantation of the 9th Intrepid mitral valve in the world with this smaller invasive system, St. Patrick Hospital continues to set new standards in cardiac innovation and patient-centered care.
[…] Story continues […]